# Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

> **NCT02812641** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Stage III Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** BPF-CCRT (run-in)
- **DRUG:** BPF-CCRT (randomized)
- **DRUG:** PF-CCRT (randomized)

## Key facts

- **NCT ID:** NCT02812641
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-12
- **Final completion:** 2021-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812641, "Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02812641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*